ACOR - Acorda Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Ardsley,
United States
ACOR price evolution
ACOR
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $51.45 | $65.22 | $61.92 | $71 |
| Short term investments | ||||
| Net receivables | $11.99 | $17 | $13.59 | $14.01 |
| Inventory | $14.84 | $18.55 | $20.59 | $25.36 |
| Total current assets | $80.45 | $102.16 | $97.07 | $112.94 |
| Long term investments | ||||
| Property, plant & equipment | $9.26 | $11.13 | $12.88 | $14.66 |
| Goodwill & intangible assets | $328.23 | $335.98 | $343.73 | $351.48 |
| Total noncurrent assets | $343.68 | $353.31 | $369.02 | $378.56 |
| Total investments | ||||
| Total assets | $424.14 | $455.47 | $466.09 | $491.5 |
| Current liabilities | ||||
| Accounts payable | $8.77 | $10.85 | $15.5 | $17.48 |
| Deferred revenue | ||||
| Short long term debt | $7.04 | $8.19 | $9.32 | $10.71 |
| Total current liabilities | $46 | $54.02 | $68.27 | $67.66 |
| Long term debt | $186.31 | $182.76 | $179.66 | $176.37 |
| Total noncurrent liabilities | $250.59 | $250.31 | $233.34 | $233.36 |
| Total debt | $193.34 | $190.94 | $188.98 | $187.07 |
| Total liabilities | $296.59 | $304.33 | $301.61 | $301.02 |
| Shareholders' equity | ||||
| Retained earnings | -$894.88 | -$870.36 | -$849.79 | -$822.72 |
| Other shareholder equity | -$0.57 | -$1.02 | -$1.56 | -$1.83 |
| Total shareholder equity | $127.55 | $151.14 | $164.47 | $190.48 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $65.22 | $102.89 | $105.19 | $294.1 |
| Short term investments | $63.75 | $151.99 | ||
| Net receivables | $17 | $20.19 | $22.08 | $23.43 |
| Inventory | $18.55 | $28.68 | $25.22 | $29.01 |
| Total current assets | $102.16 | $221.34 | $201.11 | $528.11 |
| Long term investments | ||||
| Property, plant & equipment | $11.13 | $25.74 | $165.98 | $60.52 |
| Goodwill & intangible assets | $335.98 | $366.98 | $402.33 | $710.63 |
| Total noncurrent assets | $353.31 | $411.35 | $598.61 | $771.56 |
| Total investments | $63.75 | $151.99 | ||
| Total assets | $455.47 | $632.68 | $799.72 | $1299.67 |
| Current liabilities | ||||
| Accounts payable | $10.85 | $12.15 | $26.26 | $48.86 |
| Deferred revenue | ||||
| Short long term debt | $8.19 | $76.58 | $8.35 | $0.62 |
| Total current liabilities | $54.02 | $137.25 | $86.39 | $140.26 |
| Long term debt | $182.76 | $183.37 | $241.26 | $343.14 |
| Total noncurrent liabilities | $250.31 | $257.47 | $402.51 | $547.43 |
| Total debt | $190.94 | $259.95 | $249.61 | $343.76 |
| Total liabilities | $304.33 | $394.73 | $488.9 | $687.68 |
| Shareholders' equity | ||||
| Retained earnings | -$870.36 | -$766.4 | -$666.81 | -$393.84 |
| Other shareholder equity | -$1.02 | -$2.8 | -$1.17 | $2.81 |
| Total shareholder equity | $151.14 | $237.96 | $310.82 | $611.98 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $22.53 | $36.97 | $31.46 | $31.79 |
| Cost of revenue | $5.97 | $4.2 | $13.3 | $11.32 |
| Gross Profit | $16.57 | $32.77 | $18.15 | $20.46 |
| Operating activities | ||||
| Research & development | $1.69 | $1.37 | $1.93 | $2.37 |
| Selling, general & administrative | $26.94 | $28.44 | $29.62 | $32.37 |
| Total operating expenses | $36.32 | $37.5 | $39.24 | $42.43 |
| Operating income | -$19.76 | -$4.73 | -$21.09 | -$21.97 |
| Income from continuing operations | ||||
| EBIT | -$16.7 | -$11.56 | -$23.01 | -$15.69 |
| Income tax expense | $0.26 | $1.67 | -$3.1 | -$0.53 |
| Interest expense | $7.56 | $7.34 | $7.17 | $7.71 |
| Net income | ||||
| Net income | -$24.52 | -$20.57 | -$27.07 | -$22.86 |
| Income (for common shares) | -$24.52 | -$20.57 | -$27.07 | -$22.86 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $129.07 | $152.97 | $192.41 | $471.43 |
| Cost of revenue | $40.79 | $33.51 | $34.85 | $99.31 |
| Gross Profit | $88.28 | $119.45 | $157.56 | $372.12 |
| Operating activities | ||||
| Research & development | $10.42 | $23.01 | $60.08 | $106.38 |
| Selling, general & administrative | $124.4 | $152.58 | $192.85 | $172.25 |
| Total operating expenses | $165.58 | $268.38 | $556.13 | $278.62 |
| Operating income | -$77.3 | -$148.92 | -$398.57 | $93.5 |
| Income from continuing operations | ||||
| EBIT | -$79.04 | -$77.09 | -$252.38 | $42.02 |
| Income tax expense | -$5.12 | -$8.07 | -$1.28 | -$13.26 |
| Interest expense | $30.04 | $30.57 | $21.87 | $21.6 |
| Net income | ||||
| Net income | -$103.95 | -$99.59 | -$272.97 | $33.68 |
| Income (for common shares) | -$103.95 | -$99.59 | -$272.97 | $33.68 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | -$24.52 | -$20.57 | -$27.07 | -$22.86 |
| Operating activities | ||||
| Depreciation | $8.53 | $8.47 | $8.32 | $8.63 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.48 | $0.48 | $0.85 | $0.95 |
| Total cash flows from operations | -$13.64 | $3.24 | -$9.01 | -$8.69 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0 | -$0.14 | |
| Investments | $73.97 | |||
| Total cash flows from investing | -$0.04 | $73.97 | -$0.14 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$73.97 | -$69 | ||
| Total cash flows from financing | -$73.97 | -$69 | ||
| Effect of exchange rate | -$0.09 | $0.06 | -$0.06 | $0.38 |
| Change in cash and equivalents | -$13.77 | $3.3 | -$9.08 | -$77.44 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$103.95 | -$99.59 | -$272.97 | $33.68 |
| Operating activities | ||||
| Depreciation | $33.95 | $41.3 | $34.57 | $11.48 |
| Business acquisitions & disposals | $7.88 | |||
| Stock-based compensation | $3 | $8.1 | $14.25 | $21.25 |
| Total cash flows from operations | -$41.35 | -$61.01 | -$128.17 | $150.79 |
| Investing activities | ||||
| Capital expenditures | -$0.17 | -$4.39 | -$90.43 | -$33.33 |
| Investments | $73.97 | $63.75 | $89.92 | -$150.83 |
| Total cash flows from investing | $73.78 | $59.36 | -$0.51 | -$176.87 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.07 | $13.45 | ||
| Net borrowings | -$69.66 | -$1.67 | -$60.48 | -$0.66 |
| Total cash flows from financing | -$69.66 | -$1.67 | -$60.55 | $12.8 |
| Effect of exchange rate | -$0.45 | $1.02 | $0.06 | -$0.41 |
| Change in cash and equivalents | -$37.67 | -$2.3 | -$189.16 | -$13.69 |
News
|
Why Acorda Therapeutics Shares Gaining Today?
Benzinga via Yahoo Finance
16 Jun 2022
|
|
78 Biggest Movers From Yesterday
Benzinga
10 Mar 2022
|
|
45 Stocks Moving In Thursday's Mid-Day Session
Benzinga
10 Mar 2022
|
|
The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit...
Benzinga
9 Mar 2022
|
|
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Benzinga
6 Mar 2022
|
|
Cuba’s bicentennial celebration back on track
Olean Times Herald
11 Feb 2022
|
|
3 Bargain Stocks to Buy and Hold Long Term
Entrpreneur
25 Oct 2021
|
|
Blocking Patents: A Patent Cannot Block Itself
The National Law Review
21 Aug 2021
|
|
Acorda: Q2 Earnings Snapshot
Olean Times Herald
5 Aug 2021
|
|
Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance
5 Aug 2021
|
Fundamentals
| Market cap | $6.37M |
|---|---|
| Enterprise value | $148.26M |
| Shares outstanding | 13.28M |
| Revenue | $122.74M |
|---|---|
| EBITDA | -$33.00M |
| EBIT | -$66.96M |
| Net Income | -$95.02M |
| Revenue Q/Q | -21.93% |
| Revenue Y/Y | -20.16% |
| P/E ratio | -0.07 |
|---|---|
| EV/Sales | 1.21 |
| EV/EBITDA | -4.49 |
| EV/EBIT | -2.21 |
| P/S ratio | 0.05 |
| P/B ratio | 0.05 |
| Book/Share | 9.65 |
| Cash/Share | 3.87 |
| EPS | -$7.16 |
|---|---|
| ROA | -20.69% |
| ROE | -59.99% |
| Debt/Equity | 2.01 |
|---|---|
| Net debt/EBITDA | -7.43 |
| Current ratio | 1.75 |
| Quick ratio | 1.43 |